• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Kiora Pharmaceuticals Inc.

    11/14/24 4:32:42 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KPRX alert in real time by email
    SC 13G 1 alyeska-kprx093024.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*



    KIORA PHARMACEUTICALS, INC.

    (Name of Issuer)

     

    Common Stock, $0.01 par value

    (Title of Class of Securities)

     

    49721T507

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  49721T507
     SCHEDULE 13G
    Page 2 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Alyeska Investment Group, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    256,408
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    256,408
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    256,408
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    8.4% *
    12
    TYPE OF REPORTING PERSON
     
    IA

    The reporting persons are the beneficial owners of 180,780 shares of Common Stock, $0.01 par value of the Issuer and hold warrants to purchase 75,628 shares of the Issuer’s Common Stock, $0.01 par value (the “Warrants”).  The percentage calculation assumes that there are currently 2,970,545 outstanding shares of Common Stock, $0.01 par value of the Issuer, based on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 9, 2024.

     


     

    CUSIP No.  49721T507
     SCHEDULE 13G
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Alyeska Fund GP, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    256,408
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    256,408
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    256,408
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    8.4%*
    12
    TYPE OF REPORTING PERSON
     
    OO

    The reporting persons are the beneficial owners of 180,780 shares of Common Stock, $0.01 par value of the Issuer and hold warrants to purchase 75,628 shares of the Issuer’s Common Stock, $0.01 par value (the “Warrants”).  The percentage calculation assumes that there are currently 2,970,545 outstanding shares of Common Stock, $0.01 par value of the Issuer, based on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 9, 2024.

     


     

    CUSIP No.  49721T507
     SCHEDULE 13G
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Anand Parekh
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    256,408
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    256,408
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    256,408
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    8.4%
    12
    TYPE OF REPORTING PERSON
     
    IN
    The reporting persons are the beneficial owners of 180,780 shares of Common Stock, $0.01 par value of the Issuer and hold warrants to purchase 75,628 shares of the Issuer’s Common Stock, $0.01 par value (the “Warrants”).  The percentage calculation assumes that there are currently 2,970,545 outstanding shares of Common Stock, $0.01 par value of the Issuer, based on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 9, 2024.
     


     

     

    CUSIP No. 49721T507
     SCHEDULE 13G
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    KIORA PHARMACEUTICALS, INC.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    332 Encinitas Blvd., Suite 102

    Encinitas, CA 92024

    Item 2.(a) Names of Person Filing:

    (i) Alyeska Investment Group, L.P.

     

    (ii) Alyeska Fund GP, LLC

     

    (iii) Anand Parekh

      

    Item 2.(b) Address of Principal Business Office:

    (i) 77 West Wacker Drive, 7th Floor

    Chicago, IL 60601

     

    (ii) 77 West Wacker Drive, 7th Floor

    Chicago, IL 60601

     

    (iii) 77 West Wacker Drive, 7th Floor

    Chicago, IL 60601

      

    Item 2.(c) Citizenship:

    (i) Alyeska Investment Group, L.P. - Delaware

     

    (ii) Alyeska Fund GP, LLC - Delaware

     

    (iii) Anand Parekh - United States of America

      

    Item 2.(d) Title of Class of Securities

    Common Stock, $0.01 par value

     

    Item 2.(e) CUSIP No.:

    49721T507

     

    CUSIP No.  49721T507
     SCHEDULE 13G
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 49721T507
     SCHEDULE 13G
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned: Please refer to items 5-9 of the cover pages attached hereto

    (b) Percent of class: Please refer to item 11 of the cover pages attached hereto

    (c) Number of shares as to which the person has: Please refer to items 5-8 of the cover pages attached hereto

    The reporting persons are the beneficial owners of 180,780 shares of Common Stock, $0.01 par value of the Issuer and hold warrants to purchase 75,628 shares of the Issuer’s Common Stock, $0.01 par value (the “Warrants”).  The percentage calculation assumes that there are currently 2,970,545 outstanding shares of Common Stock, $0.01 par value of the Issuer, based on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 9, 2024.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 49721T507
     SCHEDULE 13G
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

     

     

     

    Alyeska Investment Group, L.P.

           
      By:  /s/ Jason Bragg
        Jason Bragg, Chief Financial Officer
           
     

    Alyeska Fund GP, LLC

           
      By:  /s/ Jason Bragg
        Jason Bragg, Chief Financial Officer
     

     

    Anand Parekh

    By:  Entity and Description

           
      By:  /s/ Anand Parekh
        Anand Parekh, Individually
           

     

     
    CUSIP No. 49721T507
     SCHEDULE 13G
    Page 9 of 9 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: November 14, 2024

     

     

    Alyeska Investment Group, L.P.

           
      By:  /s/ Jason Bragg
        Jason Bragg, Chief Financial Officer
           
     

    Alyeska Fund GP, LLC

           
      By:  /s/ Jason Bragg
        Jason Bragg, Chief Financial Officer
     

     

    Anand Parekh

           
      By:  /s/ Anand Parekh
        Anand Parekh, Individually
           
    Get the next $KPRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KPRX

    DatePrice TargetRatingAnalyst
    1/19/2022$2.50Buy
    Maxim Group
    More analyst ratings

    $KPRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201

      Amendment eliminates $4.75M in near-term milestones Kiora would have owed to SentrxSentrx gains access to Kiora's recently issued patents covering the combination of KIO-201 and antibiotics for veterinary useKiora will receive a royalty on net sales of products covered by licensed patentsEncinitas, California--(Newsfile Corp. - June 15, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) ("Kiora") and Sentrx Animal Care ("Sentrx") announced today they have amended their existing licensing agreement for patents and technology related to Kiora's KIO-201 product candidate. The amended agreement between the companies eliminates up to $4.75M in near-term financial payments by Kiora to Sentrx that w

      6/15/23 7:00:00 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments

      Encinitas, California--(Newsfile Corp. - May 9, 2023) - Kiora Pharmaceuticals (NASDAQ:KPRX) announced its first quarter 2023 results, during which time it significantly advanced its ocular drug development pipeline of clinical-stage candidates for the treatment of Retinitis Pigmentosa (RP), Persistent Corneal Epithelial Defects (PCEDs), and the Ocular Presentation of Rheumatoid Arthritis (OPRA).CEO Commentary"This has been a pivotal quarter for our business resulting in several recently reported clinical development milestones," said Brian M. Strem, Ph.D., president and CEO of Kiora. "Last month we reported preliminary results from our open-label study of KIO-301, our flagship asset, demonst

      5/9/23 7:00:00 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiora Pharmaceuticals Presents Encore Imaging Results of KIO-301 for Retinitis Pigmentosa at ASNR 2023 Meeting

      Encinitas, California--(Newsfile Corp. - May 1, 2023) - Kiora Pharmaceuticals (NASDAQ:KPRX) announced today an encore presentation on KIO-301 neuroimaging results at The American Society of Neuroradiology 2023 Meeting in Chicago. The late-breaking abstract presentation titled "Functional Vision Reanimation in Retinitis Pigmentosa using an Intravitreal 'Photoswitch' Molecule (KIO-301): Functional MRI Protocol and Preliminary In-Human Observations" will be presented by Christen Barras, MBBS, Ph.D., Neuroradiologist at Jones Radiology, Associate Professor of Radiology at the University of Adelaide, in Adelaide, Australia and a co-investigator in the study.Patients with Retinitis Pigmentosa (RP)

      5/1/23 7:00:00 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KPRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Stengone Carmine N. bought $4,600 worth of shares (1,250 units at $3.68) (SEC Form 4)

      4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

      9/12/24 6:32:55 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Shapiro Aron bought $10,800 worth of shares (3,000 units at $3.60) (SEC Form 4)

      4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

      9/11/24 7:02:13 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Walters-Hoffert Lisa bought $4,825 worth of shares (1,250 units at $3.86) (SEC Form 4)

      4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

      8/20/24 1:00:12 PM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kiora Pharmaceuticals Inc.

      SC 13G/A - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

      11/14/24 7:17:24 PM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Kiora Pharmaceuticals Inc.

      SC 13G - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

      11/14/24 4:45:23 PM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Kiora Pharmaceuticals Inc.

      SC 13G - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

      11/14/24 4:32:42 PM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KPRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Inherited Retinal Disease Expert, Mark Pennesi, M.D., Ph.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board

      Encinitas, California--(Newsfile Corp. - April 21, 2023) - Kiora Pharmaceuticals (NASDAQ:KPRX) has appointed Mark Pennesi, M.D., Ph.D., the Kenneth C. Swan Endowed Professor in Ophthalmology and Molecular and Medical Genetics and the Chief of the Paul H. Casey Ophthalmic Genetics Division at the Casey Eye Institute at Oregon Health & Science University, to their Scientific Advisory Board. As a member of the Scientific Advisory Board, his expertise and insights will contribute to the company's development of new treatments and therapies for patients suffering from eye diseases, including retinitis pigmentosa, a rare inherited degenerative eye disease in which Kiora is enrolling a clinical tri

      4/21/23 7:00:00 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance

      Salt Lake City, Utah--(Newsfile Corp. - September 13, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) ("Kiora" or the "Company") has appointed Melissa Tosca as Executive Vice President of Finance. Mrs. Tosca will join the executive management team and oversee finance, SEC reporting and accounting functions as well as play a role in the company's capital markets strategy and planning. "Melissa brings to our company more than 15 years of financial and operational experience in both clinical and commercial-stage biotech and life science companies," said Brian M. Strem, Ph.D., President and CEO of Kiora. "This experience will be invaluable to our goals of advancing our development pipeline and

      9/13/22 6:45:00 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board

      Salt Lake City, Utah--(Newsfile Corp. - February 1, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX), ("Kiora" or the "Company") announced today the appointment of Erin Parsons as a new independent Director of its Board of Directors (the "Board"). Separately, the Executive Chairman, Stephen From, has informed Kiora of his voluntary resignation from the Board. These changes are effective immediately. "I am pleased to welcome Erin Parsons to our Board of Directors," said Brian M. Strem, Ph.D, President and CEO of Kiora. "Erin brings extensive commercial and strategic expertise in eyecare, a critical and complementary perspective as we continue to dedicate efforts to develop therapeutics for e

      2/1/22 6:45:00 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Kiora Pharmaceuticals with a new price target

      Maxim Group initiated coverage of Kiora Pharmaceuticals with a rating of Buy and set a new price target of $2.50

      1/19/22 8:19:46 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KPRX
    SEC Filings

    See more
    • Kiora Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)

      6/4/25 2:34:24 PM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiora Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)

      6/3/25 7:00:35 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiora Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)

      5/9/25 7:02:08 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO Tosca Melissa was granted 7,772 shares, increasing direct ownership by 57% to 21,371 units (SEC Form 4)

      4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

      4/2/25 8:29:26 PM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Development Officer Daniels Eric Joseph was granted 7,772 shares, increasing direct ownership by 42% to 26,375 units (SEC Form 4)

      4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

      4/2/25 8:28:59 PM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Strem Brian M. was granted 15,941 shares, increasing direct ownership by 53% to 46,103 units (SEC Form 4)

      4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

      4/2/25 8:28:23 PM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care